Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7749
-0.0851 (-9.90%)
Aug 14, 2025, 11:49 AM - Market open
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$82,920
Profits / Employee
-$1,087,640
Market Cap
15.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | 1 | 4.17% |
| Dec 31, 2023 | 24 | 3 | 14.29% |
| Dec 31, 2022 | 21 | 1 | 5.00% |
| Dec 31, 2021 | 20 | 8 | 66.67% |
| Dec 31, 2020 | 12 | -4 | -25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LGVN News
- 13 hours ago - Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 hours ago - Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 days ago - Longeveron Announces Closing Of Up To $17.5 Million Public Offering - GlobeNewsWire
- 5 days ago - Longeveron Announces Up To $17.5 Million Public Offering - GlobeNewsWire
- 9 days ago - Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - GlobeNewsWire
- 24 days ago - Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - GlobeNewsWire
- 5 weeks ago - Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - GlobeNewsWire
- 7 weeks ago - Longeveron® Appoints Than Powell as Chief Business Officer - GlobeNewsWire